@inproceedings{inproceedings, title  = {{Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK)}},

 url = {{}},

 year = {{2008}},

 month = {{4}},

 author = {{Dranitsaris G and Lidgren M and Lundkvist J and Coleman R}},

 volume = {{6}},

 journal = {{EJC SUPPLEMENTS}},

 issue = {{7}},

 pages = {{67-67}},

 note = {{Accessed on 2025/10/10}}}